Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD3 | P35462 | 10/20 | 0.77 |
| ▸ | DRD2 | P14416 | 10/20 | 0.77 |
| ▸ | DRD4 | P21917 | 2/20 | 0.46 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.46 |
| ▸ | HTR1A | P08908 | 1/20 | 0.45 |
| ▸ | HTR2A | P28223 | 1/20 | 0.45 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.45 |
| ▸ | HTR7 | P34969 | 1/20 | 0.45 |
| ▸ | HRH1 | P35367 | 1/20 | 0.45 |
| ▸ | HTR2B | P41595 | 1/20 | 0.45 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.44 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.42 |
| ▸ | HTR1D | P28221 | 3/20 | 0.40 |
| ▸ | HTR1B | P28222 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3348927 | 0.82 | DRD2 (1.00) | DRD3DRD2DRD4OPRM1HTR1A | |
| SCHEMBL7976739 | 0.81 | DRD3 (0.74) | DRD3DRD2DRD4OPRM1HTR1A | |
| SCHEMBL1798336 | 0.81 | DRD2 (0.50) | DRD3DRD2HTR1AHTR2ASLC6A4 | |
| SCHEMBL1795403 | 0.80 | DRD3 (0.49) | DRD3DRD2HTR1AHTR7ABCB1 | |
| SCHEMBL6369697 | 0.79 | DRD2 (0.74) | DRD3DRD2DRD4OPRM1HTR1A | |
| SCHEMBL1797089 | 0.77 | ACACB (0.49) | DRD3DRD2DRD4HTR1AHTR2A | |
| SCHEMBL7844061 | 0.76 | DRD2 (0.74) | DRD3DRD2DRD4OPRM1HTR1A | |
| SCHEMBL81130 | 0.74 | DRD2 (0.74) | DRD3DRD2DRD4OPRM1HTR1A | |
| SCHEMBL15025183 | 0.72 | DRD2 (0.62) | DRD3DRD2DRD4OPRM1HTR2A | |
| SCHEMBL4767841 | 0.71 | DRD2 (0.63) | DRD3DRD2DRD4OPRM1HTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110172212-A1 | AMINE-BASED COMPOUND AND USE THEREOF | KUREHA CORPORATION (JP) | 2011-07-14 | — | — | US | disclosed |
| US-7932281-B2 | Amine-based compound and use thereof | KUREHA CORPORATION (JP) | 2011-04-26 | — | — | US | disclosed |
| US-20070208007-A1 | Amine-Based Compound and Use Thereof | KUREHA CORPORATION (JP) | 2007-09-06 | — | — | US | disclosed |
| EP-1724263-A1 | BASIC AMINE COMPOUND AND USE THEREOF | Kureha Corporation (JP) | 2006-11-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110172212-A1 | AMINE-BASED COMPOUND AND USE THEREOF | NR0B2, NR5A2, NR1D2 | DRD3 283/4885DRD2 175/4885DRD4 834/4885 |
| US-20070208007-A1 | Amine-Based Compound and Use Thereof | NR0B2, NR5A2, NR2E1 | DRD3 435/4885DRD2 257/4885DRD4 1069/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.